Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in first partial response (PR1) or after progression if stage I/II < 1 year; stage III/IV patients are eligible after progression in CR/PR
Mantle-cell lymphoma, prolymphocytic leukemia: Eligible after initial therapy in >= CR1 or >= PR1
Large cell NHL > CR2/> second partial response (PR2):\r\n* Patients in CR2/PR2 with initial short remission (< 6 months) are eligible\r\n* These patients must be presented at PCC prior to enrollment, given potential competing eligibility on autotransplant protocols
Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:\r\n* Eligible patients with aggressive histologies (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histologies) in CR.\r\n* Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/CR/partial remission (PR) with no single lesion equal to or more than 5 cm.\r\n* Eligible patients with HL will be without progression of disease (POD) after salvage chemotherapy with no single lesion equal to or more than 5 cm.
NHL patients with resistant or refractory lymphoma (no partial remission [PR] following up to three cycles of combination chemotherapy) will not be eligible for transplant in this trial
Mature B-cell lymphoma\r\n* Follicular lymphoma and other indolent lymphoma\r\n** In >= second CR2/PR2\r\n* Diffuse large B-cell lymphoma\r\n** In >= CR2 or >= PR1\r\n** A high intermediate or high international prognostic index (IPI) (>= 2 for age-adjusted IPI or >= 3 for IPI) at diagnosis and double-hit or triple-hit lymphoma will be eligible in first CR\r\n** Transformed lymphoma from follicular lymphoma (FL) (or other indolent lymphoma) or chronic lymphocytic leukemia will be eligible if chemosensitive and bone marrow is negative\r\n* Mantle cell lymphoma\r\n** In first or greater CR or PR\r\n* Burkitt’s/Burkitt’s like\r\n** All patients except localized lymphoma will be eligible any time after initial therapy (after achievement of first complete remission), or in partial remission if they fail to achieve CR\r\n** Patients with localized (stage I or Ziegler stage A) will be eligible only if they fail to achieve CR1 or after relapse
Relapsed T-cell lymphoma that is chemotherapy sensitive in CR/partial response (PR) that has failed or ineligible for an autologous transplant
Lymphoplasmacytic lymphoma is eligible after initial therapy if chemotherapy sensitive
Relapsed T-cell lymphoma that is chemotherapy sensitive in CR/partial remission (PR) that has failed or ineligible for an autologous transplant
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia, natural killer (NK) cell malignancies are eligible after initial therapy in CR1+ or partial remission (PR1+)
Large cell non-Hodgkin lymphoma (NHL) > CR2/> PR2: Patients in CR2/PR2 with initial short remission (< 6 months) are eligible
Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
Any non-Hodgkins lymphoma (including chronic lymphocytic leukemia) or Hodgkin’s lymphoma at high-risk of relapse\r\n* Eligible patients with diffuse large cell (DLC) non-Hodgkin lymphoma (NHL) will:\r\n** Have relapsed disease following initial therapy but failed to mobilize or had bone marrow involvement and therefore are not suitable for an autologous transplant OR \r\n** Have failed an autologous transplant and be in CR after salvage chemotherapy\r\n* Eligible patients with transformed indolent NHL/CLL will: \r\n** Have complete response/partial response (CR/PR) of the large cell component of their disease after either salvage chemotherapy or an autologous transplant\r\n* Eligible patients with mantle cell NHL will: \r\n** Be high-risk as such as tumor protein 53 (p53) positivity and be in 1st CR/PR after initial therapy OR \r\n** Have relapsed disease following initial therapy and be in 2nd or 3rd CR/PR after salvage chemotherapy\r\n* Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) or CLL will have 2nd or subsequent progression (pre-allograft cytoreduction necessary but CR/PR not required)\r\n* Eligible patients with HL will be without progression of disease (POD) after salvage chemotherapy
Advanced non-Hodgkin lymphoma (NHL): A) low-grade NHL (Working Formulation A, B, C) following progression after initial therapy if asymptomatic at diagnosis (>= CR2, >= PR2; response duration < 1 year from last therapy) or if no CR was achieved (> PR1); at least one prior therapy of intermediate intensity (e.g. cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP]); B) mantle zone lymphoma after any progression following initial therapy (> CR1, > PR1); at least one prior therapy of intermediate intensity (e.g. CHOP); C) intermediate grade lymphoma (> PR2); response duration < 1 year from prior therapy; D) high-grade NHL (IWF H, I, J) after initial therapy if >= stage III at diagnosis; after any progression even if localized (stage I, II) at diagnosis with prior response duration < 1 year; E) recent chemotherapy responsiveness after treatment with >= 3 intermediate intensity regimens
Advanced Hodgkin's disease beyond PR2 (>= CR3, >= PR3): recent chemotherapy responsiveness
Multiple Myeloma (> CR2, > PR2) or after initial therapy if no prior PR: recent chemotherapy responsiveness
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy in CR1+ or PR1+
Large cell non-Hodgkin's lymphoma (NHL) > CR2/ > PR2; patients in CR2/PR2 with initial short remission (< 6 months) are eligible
Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy in CR1+ or first partial remission (PR1+)
Diffuse large cell non-Hodgkin lymphoma (NHL) > CR/> PR: patients in CR/PR with initial short remission (< 6 months) are eligible, or those who have failed/or are not eligible for autologous transplant
Lymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year
Adult patients must have a hematological malignancy, as described below:\r\n* Acute leukemias:\r\n** Acute lymphoblastic leukemia (ALL) in first complete remission (CR1) that is NOT considered favorable-risk as defined by the presence of at least one of the following:\r\n*** Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), other mixed lineage leukemia (MLL) rearrangements\r\n*** White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis,\r\n*** Recipient age older than 30 years at diagnosis,\r\n*** Time to CR greater than 4 weeks\r\n** Acute myelogeneous leukemia (AML) in first complete remission (CR1) that is NOT considered as favorable-risk; favorable risk is defined as having one of the following:\r\n*** t(8,21) without CKIT mutation\r\n*** inv(16) without CKIT mutation or t(16;16)\r\n*** Normal karyotype with mutated nucleophosmin (NPM1) and not FLT-IND\r\n*** Normal karyotype with double mutated CCAAT/enhancer binding protein alpha (CEBPA)\r\n*** Acute promyelocytic leukemia (APL) in first molecular remission at end of consolidation\r\n** Acute leukemias in second (2nd) or subsequent\r\n** Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR\r\n* Chronic myelogenous leukemia (CML) excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate\r\n* Myelodysplastic syndrome (MDS): International Prognostic Scoring System (IPSS) intermediate (Int)-2 or high risk (i.e., refractory anemia with excess blasts [RAEB], RAEB in transformation [RAEBt]) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be < 10%\r\n* Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone B-cell lymphoma or follicular lymphoma that have progressed after at least two prior therapies; patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant\r\n* Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy in CR1+ or first or greater partial remission (PR1+)\r\n* Large cell non-Hodgkin lymphoma (NHL) > CR2/> PR2; patients in CR2/PR2 with initial short remission (< 6 months) are eligible\r\n* Lymphoblastic lymphoma, Burkitt lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year\r\n* Multiple myeloma beyond PR2; patients with chromosome 13 abnormalities, first response lasting less than 6 months, or beta-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy\r\n* Natural killer (NK) cell leukemia
NHL patients with resistant or refractory lymphoma (no partial remission [PR] following up to three cycles of combination chemotherapy) will be ineligible for transplant in this trial
Follicular lymphoma\r\n* Patients will be eligible in >= first CR/PR (if treatment is delayed until clinically required)\r\n* Patients who are treated at diagnosis (without clinical symptoms necessitating treatment, such as B symptoms, bulky disease, marrow or other organ compromise) will be eligible in >= second CR/PR
Mantle cell lymphoma\r\n* All patients will be eligible in first or greater CR or PR
PARTS A AND B: Patients with Hodgkin lymphoma (HL) are eligible for both the phase 1 and 2 portions, if they are in one of the following categories:\r\n* Primary refractory disease (i.e. no prior CR) \r\n* Very early relapse (< 6 months from the end of initial therapy, including chemotherapy ± radiation)\r\n* Advanced stage (III or IV) at diagnosis who relapse less than one year from the end of initial therapy\r\n* Note that patients with low-stage disease (IA or IIA) at initial diagnosis, who were treated with radiation alone or fewer than four cycles of chemotherapy will NOT be eligible
Relapsed, refractory, or progressive aggressive non-Hodgkin’s lymphoma (including mantle cell lymphoma), with partial response (PR) or better prior to transplantation, and autologous BMT is not recommended;\r\n* Note: Patients with Burkitt’s, atypical Burkitt’s, or acute lymphoblastic lymphoma must be in complete remission (CR)
Non-Hodgkin lymphoma (NHL)\r\n * Patients with NHL will be eligible if they fail to achieve a CR with initial chemotherapy or if they relapse following an autologous transplant\r\n * Patients who relapse following initial therapy, but are unable to undergo autologous transplantation, will also be eligible
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive
Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible after initial therapy if chemotherapy sensitive
Acute Leukemias in 2nd or subsequent CR
Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt's lymphoma: second or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
High risk hematologic malignancy\r\n* High risk acute lymphoblastic leukemia (ALL) in complete remission 1 (CR1); examples include, but not limited to: t(9;22), hypodiploid, minimal residual disease (MRD) > 1% at the end of induction, M2 or greater marrow at the end of induction, infants with mixed-lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk complete remission 2 (CR2); examples include, but not limited to t(9;22), bone marrow (BM) relapse < 36 months CR1, T-ALL, very early (< 6 months CR1) isolated central nervous system (CNS) relapse\r\n* ALL in complete remission 3 (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1 (diagnosis of AML includes myeloid sarcoma); examples include but not limited to: preceding myelodysplastic syndrome (MDS), 5q-, -5, -7, French-American-British Cooperative group (FAB) M6, FAB M7 not t(1;22), MRD > or = 5% on day 22 (AML08), MRD > 0.1% after two cycles of induction, M3 marrow after once cycle of induction, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* AML in relapse with < 25% blasts in BM\r\n* Therapy related AML, with prior malignancy in CR > 12 months\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myeloid leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* One of the following hematologic malignancies that are refractory (includes chemoresistant relapse or primary induction failure)\r\n** ALL\r\n** AML\r\n** CML (blast crisis)\r\n** Hodgkin or non-Hodgkin lymphoma
Acute leukemias in second (2nd) or subsequent remission
Biphenotypic/undifferentiated leukemias in first (1st) or subsequent complete remission (CR)
Burkitt's lymphoma: second or subsequent CR
Biphenotypic or undifferentiated leukemia in any CR or if in 1st relapse must have < 25% blasts in bone marrow (BM)
Biphenotypic or undifferentiated leukemia in any CR or if in first (1st) relapse must have < 25% blasts in BM
Burkitts lymphoma in CR2 or subsequent CR
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR
AML and ALL in 2nd or subsequent CR
Patients must have at least one of the following high-risk conditions listed below (criteria are consistent with existing criteria within Children's Oncology Group [COG] protocols):\r\n* Acute lymphocytic leukemia (ALL) in first complete remission (CR1) as defined by at least one of the following:\r\n** Hypodiploidy\r\n** Induction failure\r\n** Minimal residual disease (MRD) after consolidation\r\n* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:\r\n** High allelic ratio fms-related tyrosine kinase 3 (FLT3)/internal tandem duplications (ITD) positive (+)\r\n** Monosomy 7\r\n** Del (5q)\r\n** Standard risk cytogenetics with positive minimal residual disease at the end of Induction I chemotherapy (for patients being treated on or according to COG AAML1031 who have had MRD studies sent to Seattle or performed at their local institution where the flow assay is sensitive enough to detect >= 0.1% blasts)\r\n* Acute leukemias in 2nd or subsequent complete remission (CR) (CR >= 2)\r\n* Mixed phenotype/undifferentiated leukemias in 1st or subsequent CR\r\n* Secondary or therapy related leukemias in CR >= 1\r\n* Natural killer (NK) cell leukemia or NK cell lymphoblastic leukemia/lymphoma CR >= 1\r\n* Myelodysplastic syndrome (MDS)\r\n* Juvenile myelomonocytic leukemia (JMML) (patients are eligible if they are not eligible for COG1221)\r\n* Prior transplant eligible if =< 18 years old (yo), >= 1 year has elapsed since BMT, and patient is off immunosuppression for >= 3 months with no GVHD; patients who have had a prior chemotherapy based preparative regimen are allowed to receive a TBI based prep, regardless of their disease\r\n* No known active central nervous system (CNS) involvement or extramedullary involvement by malignancy; such disease treated into remission is permitted\r\n* Remission is defined as morphology with < 5% blasts with no morphological characteristics of acute leukemia (e.g., Auer Rods) in a bone marrow with > 20% cellularity
Relapse after achieving a CR following the first or subsequent relapse (i.e., ? 2 relapses) OR
Acute Myelogenous Leukemia (AML) in high risk 1st or subsequent CR
Biphenotypic or undifferentiated leukemia in 1st or subsequent CR
High-risk hematologic malignancy\r\n* Very high risk acute lymphocytic leukemia (ALL) in first complete remission (CR1); examples include, but not limited to hypodiploid M2 or greater marrow at the end of induction, infants with mixed lineage leukemia (MLL) fusion or t(4;11)\r\n* ALL in high risk second complete remission (CR2); examples include but not limited to bone marrow (BM) relapse < 36 months (mo); CR1, T-ALL, very early (< 6 mo CR1) isolated central nervous system (CNS) relapse\r\n* ALL in third complete remission (CR3) or subsequent\r\n* Acute myeloid leukemia (AML) in high risk CR1; examples include but not limited to preceding myelodysplastic syndromes (MDS), 5q-, -5, -7, French American British (FAB) M6, FAB M7 not t(1;22), minimal residual disease (MRD) >= 5% on day 22 (AML08), M3 marrow after induction 1, M2 marrow after two cycles of induction, fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)\r\n* AML in CR2 or subsequent\r\n* Therapy related AML, with prior malignancy in CR > 12 mo\r\n* MDS, primary or secondary\r\n* NK cell, biphenotypic, or undifferentiated leukemia in CR1 or subsequent\r\n* Chronic myelogenous leukemia (CML) in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor\r\n* Hodgkin lymphoma in CR2 or subsequent after failure of prior autologous HCT, or unable to mobilize stem cells for autologous HCT\r\n* Non-Hodgkin lymphoma in CR2 or subsequent\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Refractory hematologic malignancies (ALL, AML, CML in blast crisis, Hodgkin or non-Hodgkin lymphoma) due to chemoresistant relapse or primary induction failure\r\n* All patients with evidence of CNS leukemia must be treated and be in CNS CR to be eligible for study
Acute leukemias in 2nd or subsequent CR
Biphenotypic/undifferentiated in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt’s lymphoma in CR2 or subsequent CR
Acute leukemia in complete remission (CR)1 or second/subsequent CR
Non-Hodgkin lymphoma in high risk CR1 or subsequent CR (by clinical, cytogenetic or molecular criteria), primary induction failure (PIF) or relapsed with chemosensitive disease; SD may be included if no mass > 3 cm
Acute lymphoblastic leukemia (ALL) with any of the following:\r\n* In CR1 or subsequent complete remission (CR2, CR3, etc.)\r\n* Primary refractory or relapsed ALL with no more than one of the following adverse features according to modified CIBMTR criteria\r\n** Second or subsequent relapse\r\n** Bone marrow blasts > 25% at time of enrollment\r\n** Age > 40 years
Biphenotypic/undifferentiated/prolymphocytic leukemias in first or subsequent CR, adult T-cell leukemia/lymphoma in first or subsequent CR
Burkitt’s lymphoma in second complete remission (CR2) or subsequent CR